Trials / Recruiting
RecruitingNCT05712746
Samtasu Post-marketing General Drug Use-results Survey in Patients with Volume Overload in Heart Failure.
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,600 (estimated)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To confirm the safety of tolvaptan sodium phosphate in patients with volume overload in heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Samtasu for I.V. infusion | Drug: 8 mg/vial or 16mg/vial Dosage and Administration: The usual adult dosage of tolvaptan sodium phosphate is 16 mg once daily and intravenously infused over 1 hour. |
Timeline
- Start date
- 2023-03-03
- Primary completion
- 2025-11-30
- Completion
- 2026-05-31
- First posted
- 2023-02-03
- Last updated
- 2025-03-21
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05712746. Inclusion in this directory is not an endorsement.